Your browser doesn't support javascript.
loading
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Velikova, Galina; Morden, James P; Haviland, Joanne S; Emery, Charlotte; Barrett-Lee, Peter; Earl, Helena; Bloomfield, David; Brunt, Adrian Murray; Canney, Peter; Coleman, Robert; Verrill, Mark; Wardley, Andrew; Bertelli, Gianfilippo; Ellis, Paul; Stein, Rob; Bliss, Judith M; Cameron, David.
Afiliação
  • Velikova G; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds Cancer Centre, St James's University Hospital, Leeds, UK. Electronic address: g.velikova@leeds.ac.uk.
  • Morden JP; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds Cancer Centre, St James's University Hospital, Leeds, UK.
  • Haviland JS; Institute of Cancer Research Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK.
  • Emery C; Institute of Cancer Research Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK.
  • Barrett-Lee P; Department of Oncology, Velindre University NHS Trust, Cardiff, UK.
  • Earl H; Department of Oncology, University of Cambridge, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
  • Bloomfield D; Department of Oncology, University Hospitals Sussex, Brighton, UK.
  • Brunt AM; School of Medicine, University of Keele, Keele, UK; Department of Oncology, University Hospitals of North Midlands, Stoke-on-Trent, UK.
  • Canney P; Beatson Oncology Center, Glasgow, UK.
  • Coleman R; Department of Oncology, Weston Park Hospital, Sheffield, UK.
  • Verrill M; Department of Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.
  • Wardley A; Outreach Research and Innovation Group, Manchester, UK.
  • Bertelli G; Department of Oncology, University Hospitals Sussex, Brighton, UK.
  • Ellis P; King's College London and Leaders in Oncology Care, London, UK.
  • Stein R; University College London Hospitals, London, UK.
  • Bliss JM; Institute of Cancer Research Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK.
  • Cameron D; University of Edinburgh Cancer Centre, Institute of Genetics and Cancer, Western General Hospital, Edinburgh, UK.
Lancet Oncol ; 24(12): 1359-1374, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37926100
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article